Showing 7371-7380 of 7484 results for "".
- Warning for Blood Clot Risk Added to Drospirenone OCPshttps://practicaldermatology.com/news/20120411-warning_for_blood_clot_risk_added_to_drospirenone_ocps/2459827/The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred t
- Olympic Swimmer Dara Torres Named Brand Ambassador for AmLactinhttps://practicaldermatology.com/news/20120329-olympic_swimmer_dara_torres_named_brand_ambassador_for_amlactin/2459830/AmLactin Alpha-Hydroxy Skin Care is kicking off the new “Ultra Skin Performance” campaign (Upsher-Smith Laboratories, Inc.) and has named 12-time Olympic medalist Dara Torres its first-ever brand ambassador . The “Ultra Skin Performance” campaign educates women of all ages about the internal and ext
- Prostaglandin D2 A Potential New Target for Alopecia Therapyhttps://practicaldermatology.com/news/20120326-prostaglandin_d2_a_potential_new_target_for_alopecia_therapy/2459832/Prostaglandin D2 (PGD2) appears to inhibit hair growth in androgenetic alopecia (AGA) and may be potential target for its treatment, new research suggests (Sci Transl Med. 4(126):126ra34). Researchers show that PG
- Skinvisible Granted Patent for UVA Absorberhttps://practicaldermatology.com/news/20120320-skinvisible_granted_patent_for_uva_absorber/2459836/Skinvisible Pharmaceuticals, Inc. has been granted a new patent for its UVA sunscreen absorber. Skinvisible's new formulation with avobenzone provides eight hours of photostability, an advantage for those who spend many hours in the sun. The ingredi
- Ulthera Cleared in Mexicohttps://practicaldermatology.com/news/20120320-ulthera_cleared_in_mexico/2459837/Ulthera is now registered in Mexico to market and distribute its ultrasound therapy device, the Ulthera System. In Mexico, the system is now prescribed to produce stimulation in tissues to raise the temperature in a localized manner for aesthetic
- Galderma Completes Phase 3 Rosacea Erythema Studyhttps://practicaldermatology.com/news/20120320-galderma_completes_of_phase_3_rosacea_erythema_study/2459839/Galderma Laboratories announced the completion of two independent Phase 3 clinical trials that evaluated the safety and efficacy of CD07805/47, a proprietary topical gel under investigation in patients with moderate to severe facial erythema of
- DUSA Launches “Spot the Signs of AK” Campaignhttps://practicaldermatology.com/news/20120320-dusa_launches_spot_the_signs_of_ak_campaign/2459840/DUSA Pharmaceuticals, Inc. introduced a new campaign called “Spot the Signs of AK” to boost awareness for actinic keratosis. The goal of the campaign is to inform the public about the dangers of cumulative sun damage and how it can cause AKs.
- Commercialization of MelaFind Now Underwayhttps://practicaldermatology.com/news/20120314-commercialization_of_melafind_now_underway/2459843/MELA Sciences, Inc. (NASDAQ: MELA) this week announced that the company has begun commercialization of MelaFind, as part of a controlled and deliberate launch in the U.S. and in Germany. "We are enthusiastic about the success of our final b
- ASLMS to Honor David J. Cuccia, PhDhttps://practicaldermatology.com/news/20120314-aslms_to_honor_david_j_cuccia_phd/2459844/David J. Cuccia, Ph.D, Chief Technology Officer and CEO at Modulated Imaging, Inc. Irvine, California, will receive the 2012 Dr. Horace Furumoto Innovations Professional Development Grant at the Annual Conference of the American Society for Laser Medicine and Surgery
- Merz Clarifies Status of Xeomin, Appoints William (Bill) Humphries CEOhttps://practicaldermatology.com/news/20120314-merz_clarifies_status_of_xeomin_appoints_new_ceo/2459845/Following a hearing in US District Court yesterday, Merz, Inc. is clarifying the availability of Xeomin and has appointed William (Bill) D. Humphries as CEO of Merz Inc., effective March 15. Merz Pharmaceuticals, LLC will continue to sell Xeomin fo